Carl Zeiss Meditec SOTP model

Interactive tool
Segment assumptions
MCS Microsurgery
Revenue: €504m | Current EBITA: €71m (14.0%)
DCF EV
Legacy OPT Ophthalmology ex-DORC
Revenue: ~€1,514m | Est. EBITA: ~€137m (~9.0%)
DCF EV
DORC Vitreoretinal
Revenue: ~€210m | Est. EBITA: ~€50m (~24%)
DCF EV
Shared assumptions & EV bridge
DCF parameters
EV to equity bridge
Valuation output
EV composition
SOTP summary
EV (€m)EV/EBITA
Acquisition value test
€m
This interactive model is provided for educational and analytical purposes only and does not constitute investment advice. All assumptions are user-adjustable and should be validated against primary sources. Base financials reference FY 2024/25 reported figures. The Boredom Baron and contributing analysts accept no liability for investment decisions made using this tool. DORC acquisition cost: €985m (April 2024). See the accompanying deep-dive article for full methodology and risk discussion.